{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:11:51Z","timestamp":1780333911192,"version":"3.54.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jiph.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T10:58:01Z","timestamp":1619866681000},"page":"910-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-6727","authenticated-orcid":false,"given":"Madhusudan","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4952-6081","authenticated-orcid":false,"given":"Nisha","family":"Tewatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemlata","family":"Vashisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-833X","authenticated-orcid":false,"given":"Reena","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudershan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2021.04.011_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature22975","article-title":"Host and viral traits predict zoonotic spillover from mammals","volume":"546","author":"Olival","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2021.04.011_bib0010","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1002\/slct.202001709","article-title":"COVID-19: emergence of infectious diseases, nanotechnology aspects, challenges, and future perspectives","volume":"5","author":"Gupta","year":"2020","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.jiph.2021.04.011_bib0015","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s11427-017-9241-3","article-title":"Human T-cell immunity against the emerging and re-emerging viruses","volume":"60","author":"Zhao","year":"2017","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nature06536","article-title":"Global trends in emerging infectious diseases","volume":"451","author":"Jones","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2021.04.011_bib0025","first-page":"174","article-title":"SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview","volume":"28","author":"Rabaan","year":"2020","journal-title":"Infez Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0030","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/ppul.24810","article-title":"Overview: the history and pediatric perspectives of severe acute respiratory syndromes: novel or just like SARS","volume":"55","author":"Hon","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0035","first-page":"6","article-title":"Emerging coronaviruses: first SARS, second MERS and third SARS-COV-2. Epidemiological updates of COVID-19","volume":"28","author":"Halaji","year":"2020","journal-title":"Infez Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jmv.25674","article-title":"Recent advances in the detection of respiratory virus infection in humans","volume":"92","author":"Zhang","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jiph.2021.04.011_bib0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.coviro.2018.12.007","article-title":"Viruses in bats and potential spillover to animals and humans","volume":"34","author":"Wang","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3855\/jidc.12671","article-title":"The novel zoonotic COVID-19 pandemic: an expected global health concern","volume":"14","author":"Contini","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.jiph.2021.04.011_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.00181","article-title":"Current and future point-of-care tests for emerging and new respiratory viruses and future perspectives","volume":"10","author":"Nelson","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0065","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S2213-2600(20)30161-2","article-title":"Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations","volume":"8","author":"Phua","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjms.2020.05.006","article-title":"A comprehensive review of manifestations of novel coronaviruses in the context of deadly COVID-19 global pandemic","volume":"360","author":"Gulati","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0075","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/ajcp\/aqaa029","article-title":"Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19","volume":"153","author":"Guarner","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0080","first-page":"2012","article-title":"Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV","volume":"24","author":"Meo","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0085","series-title":"Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.jiph.2021.04.011_bib0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.antiviral.2013.08.016","article-title":"Clinical management and infection control of SARS: lessons learned","volume":"100","author":"Cheng","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jiph.2021.04.011_bib0095","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jiph.2021.04.011_bib0100","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jinf.2004.07.010","article-title":"Medical treatment of viral pneumonia including SARS in immunocompetent adult","volume":"49","author":"Cheng","year":"2004","journal-title":"J Infect"},{"key":"10.1016\/j.jiph.2021.04.011_bib0105","first-page":"1","article-title":"Management of critically ill patients with severe acute respiratory syndrome (SARS)","volume":"1","author":"Arthur Chun-Wing","year":"2012","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0110","series-title":"MERS situation update, January 2020","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.jiph.2021.04.011_bib0115","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle east respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2021.04.011_bib0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tmaid.2019.06.012","article-title":"A systematic review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","volume":"30","author":"Momattin","year":"2019","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.jiph.2021.04.011_bib0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13063-019-3846-x","article-title":"Treatment of Middle East respiratory syndrome with a combination of lopinavir\/ritonavir and interferon-\u03b21b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial","volume":"21","author":"Arabi","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jiph.2021.04.011_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0135","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2021.04.011_bib0140","series-title":"WHO coronavirus disease (COVID-19) dashboard","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.jiph.2021.04.011_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2020-4-15","article-title":"Coronavirus disease 2019 (COVID-19): latest developments in potential treatments","volume":"9","author":"Hon","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.jiph.2021.04.011_bib0150","doi-asserted-by":"crossref","DOI":"10.1007\/s12038-020-00067-w","article-title":"Drug targets for COVID-19 therapeutics: ongoing global efforts","volume":"45","author":"Saxena","year":"2020","journal-title":"J Biosci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0155","first-page":"1","article-title":"COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus department of pharmacy services","author":"Song","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2021.04.011_bib0160","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3390\/ijms21072657","article-title":"A review of sars-cov-2 and the ongoing clinical trials","volume":"21","author":"Tu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.jiph.2021.04.011_bib0170","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0175","first-page":"1","article-title":"Remdesivir for the treatment of Covid-19 \u2014 preliminary report","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0180","first-page":"1","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"0","author":"Du","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiph.2021.04.011_bib0185","first-page":"5","article-title":"Experimental treatment with Favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.jiph.2021.04.011_bib0190","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0195","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2021.04.011_bib0200","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jiph.2021.04.011_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpubh.2020.00249","article-title":"Effectiveness of arbidol for COVID-19 prevention in health professionals","volume":"8","author":"Yang","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.jiph.2021.04.011_bib0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.jiph.2021.04.011_bib0215","first-page":"1","article-title":"Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission\u2014a preliminary report of a retrospective cohort study","volume":"40","author":"Nong Zhang","year":"2020","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0220","first-page":"1","article-title":"The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro","volume":"0","author":"Bukreyeva","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.jiph.2021.04.011_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104874","article-title":"Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management","volume":"157","author":"Kelleni","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jiph.2021.04.011_bib0230","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jiph.2021.04.011_bib0235","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4269\/ajtmh.20-0271","article-title":"Ivermectin and COVID-19: keeping rigor in times of urgency","volume":"102","author":"Chaccour","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jiph.2021.04.011_bib0240","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jiph.2021.04.011_bib0245","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus","volume":"5883","author":"Sheahan","year":"2020","journal-title":"Science (80)"},{"key":"10.1016\/j.jiph.2021.04.011_bib0250","doi-asserted-by":"crossref","DOI":"10.3390\/v12050525","article-title":"Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2\u2019-O-methylation of viral RNA","volume":"12","author":"Encinar","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jiph.2021.04.011_bib0255","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.18632\/oncotarget.26831","article-title":"Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts","volume":"10","author":"Delgado-Calle","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.jiph.2021.04.011_bib0260","series-title":"Vir and alnylam identify RNAi therapeutic development candidate, VIR-2703 (ALN-COV), targeting SARS-CoV-2 for the treatment of COVID-19, 2703","author":"Pharmaceuticals","year":"2020"},{"key":"10.1016\/j.jiph.2021.04.011_bib0265","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0270","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2021.04.011_bib0275","first-page":"2018","article-title":"The benefits of chloroquine multi-mechanisms of action on the nervous system","volume":"3","author":"Abdulkadir","year":"2019","journal-title":"Theranostics Brain Spine Neural Disord"},{"issue":"4","key":"10.1016\/j.jiph.2021.04.011_bib0280","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jiph.2021.04.011_bib0285","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s12291-020-00900-x","article-title":"Hydroxychloroquine and Covid-19: a cellular and molecular biology based update","volume":"35","author":"Pal","year":"2020","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.jiph.2021.04.011_bib0290","first-page":"1","article-title":"Targeted update: safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19","volume":"0","author":"Cochrane","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiph.2021.04.011_bib0295","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41419-020-2721-8","article-title":"Is hydroxychloroquine beneficial for COVID-19 patients?","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jiph.2021.04.011_bib0300","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.18203\/2319-2003.ijbcp20203153","article-title":"Status of chloroquine and hydroxychloroquine in COVID-19 infection","volume":"9","author":"Shahani","year":"2020","journal-title":"Int J Basic Clin Pharmacol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/abt\/tbaa007","article-title":"Antibody therapies for the treatment of COVID-19","volume":"3","author":"Ku","year":"2020","journal-title":"Antibody Ther"},{"key":"10.1016\/j.jiph.2021.04.011_bib0310","doi-asserted-by":"crossref","first-page":"102768","DOI":"10.1016\/j.ebiom.2020.102768","article-title":"Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development","volume":"55","author":"de Alwis","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jiph.2021.04.011_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102790","article-title":"Treatment for emerging viruses: convalescent plasma and COVID-19","volume":"59","author":"Brown","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0320","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2021.04.011_bib0325","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.18632\/aging.103102","article-title":"Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19","volume":"12","author":"Zhang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jiph.2021.04.011_bib0330","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jiph.2021.04.011_bib0335","first-page":"1","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"9913","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0340","first-page":"1","article-title":"Articles Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2021.04.011_bib0345","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"van Doremalen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.jiph.2021.04.011_bib0350","first-page":"1","article-title":"An evidence based perspective on mRNA-SARScov-2 vaccine development","volume":"26","author":"Wang","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jiph.2021.04.011_bib0355","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2-preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0360","series-title":"Judith Absalon","first-page":"1","author":"Lockhart","year":"2020"},{"key":"10.1016\/j.jiph.2021.04.011_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jiph.2021.04.011_bib0370","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1021\/acsnano.0c03697","article-title":"Toward nanotechnology-enabled approaches against the COVID-19 pandemic","volume":"14","author":"Weiss","year":"2020","journal-title":"ACS Nano"},{"issue":"6499","key":"10.1016\/j.jiph.2021.04.011_bib0375","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Rapid development of an inactivated vaccine for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Sci"},{"key":"10.1016\/j.jiph.2021.04.011_bib0380","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"81","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jiph.2021.04.011_bib0385","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"6736","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2021.04.011_bib0390","first-page":"1","article-title":"Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open\u00adlabel cohort study","author":"Torre","year":"2020","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.jiph.2021.04.011_bib0395","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ejhpharm-2020-002322","article-title":"Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19","volume":"27","author":"Palanques-Pastor","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jiph.2021.04.011_bib0400","doi-asserted-by":"crossref","first-page":"2001919","DOI":"10.1183\/13993003.01919-2020","article-title":"JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk","volume":"56","author":"Mehta","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiph.2021.04.011_bib0405","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0410","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.str.2015.12.015","article-title":"Family-wide structural analysis of human numb-associated protein kinases","volume":"24","author":"Sorrell","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.jiph.2021.04.011_bib0415","first-page":"3","article-title":"Statin therapy in COVID-19 infection: much more than a single pathway","author":"Bifulco","year":"2020","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"issue":"4","key":"10.1016\/j.jiph.2021.04.011_bib0420","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ehjcvp\/pvaa042","article-title":"Statin therapy in COVID-19 infection","volume":"6","author":"Castiglione","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jiph.2021.04.011_bib0425","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.200645","article-title":"Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis","volume":"192","author":"Ye","year":"2020","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.jiph.2021.04.011_bib0430","first-page":"4","article-title":"CD24Fc protects against viral pneumonia in simian immunodeficiency virus-infected Chinese rhesus monkeys","author":"Tian","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jiph.2021.04.011_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jiph.2021.04.011_bib0440","doi-asserted-by":"crossref","first-page":"m2648","DOI":"10.1136\/bmj.m2648","article-title":"Dexamethasone in the management of covid-19","volume":"370","author":"Johnson","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jiph.2021.04.011_bib0445","article-title":"Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report","author":"Horby","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.jiph.2021.04.011_bib0450","first-page":"3","article-title":"What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19?","author":"Bauer","year":"2020","journal-title":"Cleveland Clinic J Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12051466","article-title":"Covid-19: the inflammation link and the role of nutrition in potential mitigation","volume":"12","author":"Zabetakis","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jiph.2021.04.011_bib0460","first-page":"1","article-title":"Evidence that vitamin d supplementation could reduce risk of influenza and COVID-19 infections and deaths","author":"Grant","year":"1980","journal-title":"Nutrients"},{"key":"10.1016\/j.jiph.2021.04.011_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-02851-4","article-title":"A new clinical trial to test high-dose vitamin C in patients with COVID-19","volume":"24","author":"Carr","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.jiph.2021.04.011_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-019-2538-y","article-title":"Vitamin C administration in the critically ill: a summary of recent meta-analyses","volume":"23","author":"Carr","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.jiph.2021.04.011_bib0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001176","article-title":"Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture","volume":"6","author":"te Velthuis","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jiph.2021.04.011_bib0480","first-page":"1","article-title":"Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation","volume":"0","author":"Kumar","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jiph.2021.04.011_bib0485","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/acm.2020.0129","article-title":"Public health approach of ayurveda and yoga for COVID-19 prophylaxis","volume":"26","author":"Tillu","year":"2020","journal-title":"J Altern Complement Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0490","doi-asserted-by":"crossref","first-page":"101214","DOI":"10.1016\/j.ctcp.2020.101214","article-title":"A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19)","volume":"40","author":"Mirzaie","year":"2020","journal-title":"Complement Ther Clin Pract"},{"key":"10.1016\/j.jiph.2021.04.011_bib0495","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.antiviral.2005.02.007","article-title":"Identification of natural compounds with antiviral activities against SARS-associated coronavirus","volume":"67","author":"Li","year":"2005","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jiph.2021.04.011_bib0500","doi-asserted-by":"crossref","first-page":"100407","DOI":"10.1016\/j.imr.2020.100407","article-title":"Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines","volume":"9","author":"Ang","year":"2020","journal-title":"Integr Med Res"},{"issue":"7","key":"10.1016\/j.jiph.2021.04.011_bib0505","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.apsb.2020.05.007","article-title":"Analysis on herbal medicines utilized for treatment of COVID-19","volume":"10","author":"Luo","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jiph.2021.04.011_bib0510","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1021\/acsomega.0c00772","article-title":"Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil","volume":"5","author":"Thuy","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.jiph.2021.04.011_bib0515","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbi.2020.05.003","article-title":"Time to realise the true potential of Ayurveda against COVID-19","volume":"87","author":"Golechha","year":"2020","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jiph.2021.04.011_bib0520","first-page":"1","article-title":"Ayurvedic clinical profile of COVID-19 \u2013 a preliminary report","author":"Rammanohar","year":"2020","journal-title":"J Ayurveda Integr Med"},{"key":"10.1016\/j.jiph.2021.04.011_bib0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1758788","article-title":"Novel 2019 Coronavirus structure, mechanism of action, antiviral drug promises and rule out against it\u2019s treatment","volume":"38","author":"Boopathi","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jiph.2021.04.011_bib0530","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Durg repurposing approach to fight covid-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.jiph.2021.04.011_bib0535","doi-asserted-by":"crossref","first-page":"E254","DOI":"10.3390\/v12030254","article-title":"Preliminary identifca-tion of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603412100112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603412100112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:11:24Z","timestamp":1761750684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187603412100112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":107,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S187603412100112X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2021.04.011","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}